<DOC>
	<DOCNO>NCT02011620</DOCNO>
	<brief_summary>Type 2 diabetes mellitus ( DM ) become lead global epidemic . DM affect several system body . Most complication encounter DM attribute uncontrolled hyperglycemia poor glycemic control . Hyperglycemic stress tend damage inner line small blood vessel ( endothelium ) . Normally , endothelium release chemical substance call nitric oxide ( NO ) relax blood vessel also prevents blockade vessel . Therefore damage endothelium ( endothelial dysfunction ) result diminish level NO ultimately lead occlusion small blood vessel ( microvascular occlusion ) . Microvascular occlusion vessel supply eye , kidney nerve lead serious complication like diabetic retinopathy , nephropathy neuropathy . Of late , skeletal system emerge another vulnerable target diabetic microvascular disease . Patients DM increase risk develop fracture . Certain predispose factor like diabetic neuropathy visual disturbance ( retinopathy cataract ) increase likelihood fracture DM . More recently , evolve research demonstrate NO 's prospective role bone preservation . Earlier study also validate use nitrate ( donor NO ) improve bone strength reduce risk fracture . So far study investigated effect nitrate endothelial function bone microarchitecture patient diabetes . The investigator therefore propose investigate influence nitrate endothelial dysfunction bone integrity patient type 2 diabetes . 40 patient type 2 DM recruit study ; 20 patient receive 20 mg oral isosorbide mononitrate daily 20 receive study drug . The investigator hope demonstrate improvement endothelial function ( measure skin blood flow ) bone integrity ( measure marker bone formation bone resorption bone mineral density - BMD ) follow 6 month nitrate therapy .</brief_summary>
	<brief_title>Influence Nitrates Bone Remodeling Endothelial Function Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Diabetes mellitus ( DM ) chronic debilitate disease affect almost system body accompany diabetic complication ( neuropathy , retinopathy nephropathy ) add global burden DM . These diabetic complication arise manifestation hyperglycaemic damage induce cellular level particularly endothelial cell ( EC ) . Exposure hyperglycaemic stress cause endothelial dysfunction , major perpetrator microvascular disease . Disruption endothelial function also mark advent subsequent development cardiovascular disease ( CVD ) include atherosclerosis coronary artery disease ( CAD ) . Microvascular disease occur result deficiency potent endothelial vasodilator , nitric oxide ( NO ) . NO plays fundamental role vascular regulation mediate vasodilation . Other favourable characteristic NO include antiplatelet activity prevention vascular smooth muscle cell ( VSMC ) proliferation . Unsurprisingly , diminish NO level DM eventually lead occlusion microvasculature retina , glomerulus peripheral nerve ( vasa nervorum ) . Of late , skeletal system also emerge another vulnerable target diabetic microvascular disease . Certain predispose factor like diabetic neuropathy ( DN ) , visual disturbance ( retinopathy cataract ) , gait abnormality hypoglycemia increase likelihood fracture DM . Among factor DN contribute major extent development fracture especially fracture low extremity . Current antiresorptive therapy include estrogen/ HRT ( Hormone replacement therapy ) , bisphosphonates ( BPP ) , selective estrogen receptor modulators ( SERM ) denosumab ( DMB ) . These agent mainly retard bone resorption trabecular bone , minimal effect cortical bone associate 20-30 % reduction risk non-vertebral fracture . Moreover , decrease bone formation devoid adverse effect . Some agent also expensive time unavailable country . All limitation challenge discovery ideal agent prevent bone resorption , increase bone formation also reduce risk non-vertebral fracture . Lately therapeutic role organic nitrate ( source NO ) bone metabolism lead breakthrough field research . Nitrates commonly use treatment angina . Since nitrate widely available , inexpensive associate limited side effect , would practical exploit characteristic feature treatment bone disease endothelial dysfunction DM . AIMS This pilot study aim investigate effect Isosorbide mononitrate patient type 2 DM respect : - Its influence bone remodelling assess level bone marker ability improve BMD . - Its role modulate endothelial dysfunction . HYPOTHESIS In randomise pilot study , patient type 2 DM receive 20 mg Isosorbide mononitrate show : - An improvement bone formation measure serum procollagen type 1 amino terminal propeptide ( P1NP ) - Suppression bone resorption assess measurement serum C-terminal cross-linked telopeptide type-I collagen ( CTX ) - Improvement calcaneal BMD - Improvement endothelial mediate vasodilation . PATIENTS 40 female/ male subject type 2 DM consider eligible study . They recruit Tameside Diabetes Centre appropriate GP practice write consent obtain prior participation study . Since placebo study , research fellow research nurse blind treatment patient receive . As known duration diabetes affect microvascular circulation possibly bone metabolism , two group match follow variable : age , gender , duration diabetes severity neuropathy . Diabetes self-education management along dietary advice provide participant study . RANDOMISATION With help computer-generated program study participant randomise 2 group : - Group 1 : 20 subject receive 20 mg/day isosorbide mononitrate orally - Group 2 : 20 subject receive standard care MEASUREMENTS Biochemical parameter baseline 6 month later - Serum procollagen type 1 amino terminal propeptide ( P1NP ) , marker bone formation indicate osteoblastic activity . - Serum C-terminal cross-linked telopeptide type-I collagen ( CTX ) , marker bone resorption Clinical parameter baseline - Laser Doppler image - Calcaneal BMD ( Sahara clinical bone sonometer ; Hologic , Waltham , MA ) Blood sample obtain antecubital vein follow overnight fast rest 15 minute supine position . Assessment microcirculation Laser Doppler Iontophoresis baseline 6 month A standard measurement microcirculation laser Doppler iontophoresis , use several research institute . In trial skin microcirculation measure ventral aspect forearm use Perimed Laser Doppler imager iontophoresis system . Endothelial-mediated vasodilation measure iontophoresis acetylcholine , sodium nitroprusside used measure endothelium-independent vasodilation . The iontophoresis system consist ION chamber ( iontophoresis delivery vehicle device ) stick firmly skin reference electrode . The response blood flow image quantified use Perimed Laser Doppler Imager ( Sweden ) . Assessment calcaneal BMD baseline 6 month This simple convenient method assess peripheral BMD ass fracture risk . The device use quantitative ultrasound call Sahara Clinical Bone Sonometer ( Sahara Clinical Bone Sonometer ; Hologic , Waltham , MA ) . The calcaneus preferred peripheral site assess fracture risk . This device use ultrasound wave determine BMD calcaneus . In procedure , bare heel place device , BMD calculate within 30 second result generate paper device . STATISTICAL ANALYSIS The result obtain study report difference baseline 6 month later follow single daily oral dose 20 mg isosorbide mononitrate . The difference 2 group also infer end 6 month . The change skeletal parameter ( serum P1NP CTX ) microcirculation compare 2 group use t-tests determine post hoc difference . A p-value &lt; 0.05 consider significant . All analysis conduct use Statistical Package Social Sciences ( SPSS Inc. , Chicago , Illinois , USA ) . DURATION OF THE STUDY The estimated time enrolment patient within 6 month . The duration study 6 month last follow end 12 month .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Isosorbide-5-mononitrate</mesh_term>
	<mesh_term>Isosorbide Dinitrate</mesh_term>
	<mesh_term>Isosorbide</mesh_term>
	<criteria>Females male age 4075 year A diagnosis type 2 DM base one follow criterion ( ADA 2010 ) : Fasting plasma glucose ( FPG ) &gt; = 126 mg/dL ( 7.0 mmol/L ) 2h plasma glucose &gt; = 200 mg/dl ( 11.1 mmol/L ) OGTT Classic symptoms hyperglycemia hyperglycemic crisis random plasma glucose &gt; = 200 mg/dL ( 11.1 mmol/L ) . Known history type 2 diabetes mellitus treatment At screening , age 40 year 75 year . Pregnancy lactation Type 1 diabetes mellitus ( patient history ketoacidosis , age onset DM 25 year age , BMI &lt; 21 kg/m2 use insulin without concomitant oral hypoglycemic agent ) Patients uncontrolled hypertension ( systolic blood pressure [ SBP ] &gt; 160/90 mmHg ) hypotension ( SBP &lt; =100 mm Hg ) screening . History hypersensitivity nitrate History low blood pressure History raise intracranial pressure ( cerebral haemorrhage head trauma ) History cardiovascular disease ( ischaemic heart disease , previous stroke severe peripheral vascular disease [ Ankle brachial pressure index ABPI &lt; 0.7 ] ) History acute circulatory failure ( shock ) , circulatory collapse , cardiogenic shock History hypertrophic obstructive cardiomyopathy , constrictive pericarditis , cardiac tamponade , low cardiac filling pressure , aortic/ mitral valve stenosis History general systemic illness include cardiac , hepatic renal insufficiency Patients clinical nephropathy ( 24 hour protein &gt; 0.5g dipstix protein + ) renal failure ( serum creatinine &gt; 130 Âµmol/l ) . History anaemia History close angle glaucoma History migraine headache History hypothyroidism History hypothermia History malnutrition History Paget 's disease metabolic bone disorder History coeliac inflammatory bowel disease History multiple myeloma cancer History nitrate use cardiac condition History treatment phosphodiesterase type5 inhibitor History foot ulcer History active foot deformity e.g . Charcot foot History glucocorticoid intake within last 3 month History hormone replacement therapy last 12 month History treatment SERM ( selective estrogen receptor modulator ) History treatment thiazolidinedione History anticonvulsant use History past current treatment osteoporosis History bisphosphonate therapy within last 3 year</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>